CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Impairment of Long-Lived Assets Held-for-use
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) reported Impairment of Long-Lived Assets Held-for-use of $26.28 million for the 6-month period ending 2026-06-27, per its 10-Q filed 2026-08-05.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ImpairmentOfLongLivedAssetsHeldForUse · last filed 2026-08-05
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. impairment of long-lived assets held-for-use for the quarter ending 2026-06-27 was $10.42M, a 49.50% decline year-over-year.
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. impairment of long-lived assets held-for-use for the quarter ending 2026-03-28 was $15.86M, a 49.99% increase year-over-year.
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. impairment of long-lived assets held-for-use for the quarter ending 2025-12-27 was $222.90M, a 546.33% increase year-over-year.
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. impairment of long-lived assets held-for-use for the quarter ending 2025-09-27 was $4.98M, a 61.28% increase year-over-year.
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. impairment of long-lived assets held-for-use for fiscal 2025 was $259.08M, a 399.91% increase from fiscal 2024.
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. impairment of long-lived assets held-for-use for fiscal 2024 was $51.83M, a 23.65% increase from fiscal 2023.
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. impairment of long-lived assets held-for-use for fiscal 2023 was $41.91M, a 620.62% increase from fiscal 2022.
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. impairment of long-lived assets held-for-use for fiscal 2022 was $5.82M, a 693.45% increase from fiscal 2021.
| Period end | Impairment of Long-Lived Assets Held-for-use 3 month | Impairment of Long-Lived Assets Held-for-use 6 month | Impairment of Long-Lived Assets Held-for-use 9 month | Impairment of Long-Lived Assets Held-for-use 12 month |
|---|---|---|---|---|
| 2026-06-27 | $10.42M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $26.28M 10-Q · filed 2026-08-05 | $249.17M derived: sum of 3 quarters · filed 2026-08-05 | $254.16M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-28 | $15.86M 10-Q · filed 2026-05-07 | $238.76M derived: sum of 2 quarters · filed 2026-05-07 | $243.74M derived: sum of 3 quarters · filed 2026-05-07 | $264.37M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-27 | $222.90M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-18 | $227.88M derived: sum of 2 quarters · filed 2026-02-18 | $248.50M derived: sum of 3 quarters · filed 2026-08-05 | $259.08M 10-K · filed 2026-02-18 |
| 2025-09-27 | $4.98M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $25.61M derived: sum of 2 quarters · filed 2026-08-05 | $36.19M 10-Q · filed 2025-11-05 | $70.67M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-28 | $20.63M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $31.20M 10-Q · filed 2026-08-05 | $65.69M derived: sum of 3 quarters · filed 2026-08-05 | $68.78M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-29 | $10.58M 10-Q · filed 2026-05-07 | $45.06M derived: sum of 2 quarters · filed 2026-05-07 | $48.15M derived: sum of 3 quarters · filed 2026-05-07 | $56.97M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-28 | $34.49M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-18 | $37.58M derived: sum of 2 quarters · filed 2026-02-18 | $46.39M derived: sum of 3 quarters · filed 2026-02-18 | $51.83M 10-K · filed 2026-02-18 |
| 2024-09-28 | $3.09M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $11.91M derived: sum of 2 quarters · filed 2025-11-05 | $17.34M 10-Q · filed 2025-11-05 | $33.05M derived: sum of 4 quarters · filed 2026-02-18 |
| 2024-06-29 | $8.82M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | $14.25M 10-Q · filed 2025-08-06 | $29.96M derived: sum of 3 quarters · filed 2026-02-18 | $45.71M derived: sum of 4 quarters · filed 2026-02-18 |
| 2024-03-30 | $5.43M 10-Q · filed 2025-05-07 | $21.14M derived: sum of 2 quarters · filed 2026-02-18 | $36.89M derived: sum of 3 quarters · filed 2026-02-18 | $36.88M derived: sum of 4 quarters · filed 2026-02-18 |
| 2023-12-30 | $15.71M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-18 | $31.46M derived: sum of 2 quarters · filed 2026-02-18 | $31.45M derived: sum of 3 quarters · filed 2026-02-18 | $41.91M 10-K · filed 2026-02-18 |
| 2023-09-30 | $15.75M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $15.74M derived: sum of 2 quarters · filed 2024-11-06 | $26.20M 10-Q · filed 2024-11-06 | $32.02M derived: sum of 4 quarters · filed 2025-02-19 |
| 2023-07-01 | -$7.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-07 | $10.45M 10-Q · filed 2024-08-07 | $16.27M derived: sum of 3 quarters · filed 2025-02-19 | |
| 2023-04-01 | $10.46M 10-Q · filed 2024-05-09 | $16.28M derived: sum of 2 quarters · filed 2025-02-19 | ||
| 2022-12-31 | $5.82M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-19 | $5.82M 10-K · filed 2025-02-19 | ||
| 2022-09-24 | $0.00 10-Q · filed 2023-11-08 | |||
| 2021-12-25 | $733.00K 10-K · filed 2024-02-14 | |||
| 2013-12-28 | $3.80M 10-K · filed 2015-02-17 | |||
| 2012-12-29 | $3.50M 10-K · filed 2015-02-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Medpace Holdings, Inc. (MEDP) | United States | $17.316B | 30.09 |
| INCYTE CORP (INCY) | United States | $24.855B | 13.14 |
| Absci Corp (ABSI) | United States | $1.775B | -14.92 |
| OmniAb, Inc. (OABI) | United States | $0.698B | -8.05 |
| NRC HEALTH (NRC) | United States | $0.450B | 42.50 |
| MAXCYTE, INC. (MXCT) | United States | $0.124B | -3.68 |
| bioAffinity Technologies, Inc. (BIAF) | United States | $0.063B | |
| OneMedNet Corp (ONMD) | $0.042B | ||
| iSpecimen Inc. (ISPC) | United States | $0.003B | |
| FOXO TECHNOLOGIES INC. (FOXO) | United States | $0.000B | -277.71 |